Table 1.
Study and subject characteristics
| tDCS condition | Drug | Dosage (mg) | Drug intake before tDCS (h) | TMS stimulation intensity* (% of maximum stimulator output) | MEP amplitude* (μV) | tDCS stimulation duration per cycle | Number of subjects | Age of subjects * (years) | Sex of subjects (f = female, m = male) |
|---|---|---|---|---|---|---|---|---|---|
| Intra-tDCS | CBZ | 600 | 12–16/2 | 52.455 (9.512) | a: 1025.515 (91.450) | 4 s a/c | 12 | 25.067 (3.535) | f = 6; m = 6 |
| c: 991.202 (54.102) | |||||||||
| FLU | 10 | 2 | 48.182 (9.693) | a: 1005.935 (45.379) | 4 s a/c | 11 | 25.636 (3.749) | f = 5; m = 6 | |
| c: 1005.504 (45.475) | |||||||||
| DMO | 150 | 2 | 49.273 (9.253) | a: 988.433(57.194) | 4 s a/c | 12 | 25.067(3.535) | f = 6; m = 6 | |
| c: 1001.038 (66.044) | |||||||||
| PLC | 40 | 2 | FLU: 42.8 (13.580) | FLU: | 4 s a/c | FLU: 11 | FLU: 25.636 | FLU: f = 5; m = 6 | |
| Other: 49.545 (8.054) | a: 1027.303 (68.519) | Other: 12 | (3.749) | Other: f = 6; m = 6 | |||||
| c: 1039.78 (66.987) | Other: 25.067 | ||||||||
| Other: | (3.535) | ||||||||
| a: 964.023 (144.350) | |||||||||
| c: 982.620 (127.630) | |||||||||
| After-effects | CBZ | 600 | 12–16/2 | a: 41.500 (8.751) | a: 1043. 825 (103.198) | 11 min a | 10 | 26.000(2.900) | f = 2; m = 8 |
| c: 42.875 (8.323) | c: 1120.293 (140.869) | 9 min c | |||||||
| FLU | 10 | 2 | a: 44.929 (10.118) | a: 1013.445 (40.213) | 13 min a | 14 | 25.000 (4.057) | f = 7; m = 7 | |
| c: 44.429 (9.027) | c: 1016.015 (28.251) | 9 min c | |||||||
| DMO | 150 | 2 | a: 38.875 (9.015) | a:1022.356 (131.836) | 11 min a | 10 | 26.000(2.900) | f = 2; m = 8 | |
| c: 38.375 (9.070) | c: 1029.932 (149.038) | 9 min c | |||||||
| PLC | 40 | 2 | FLU: | FLU: | 11/13 min a | FLU: 14 | FLU: 25.000 | FLU: f = 7; m = 7 | |
| a: 45.308 (10.053) | a: 1019.463 (84.489) | 9 min c | Other: 10 | (4.057) | Other: f = 2; m = 8 | ||||
| c: 45.385 (9.269) | c: 1007.275 (75.679) | Other 26.000 | |||||||
| Other: | Other: | (2.900) | |||||||
| a: 40.250 (9.223) | a: 942.868 (111.506) | ||||||||
| c: 38.375 (9.591) | c: 1016.287 (132.407) |
This table illustrates the drugs applied, drug dosages, time-point of drug application relative to tDCS, TMS stimulation intensity required to achieve a baseline/non-current stimulation MEP amplitude of 1 mV, achieved baseline/non-current MEP amplitudes, tDCS duration, and number, age and sex of the subjects used for the intra- and after-effect parts of the study.
*
Values are means ± s.d. a = anodal tDCS, c = cathodal tDCS.